Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004522 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 3
- Development phase
- 319
- Enrollment target
NCT02004522: Completed Phase 3 study, sponsored by SecuraBio.
NCT02004522 is a Phase 3 study that has completed, run by SecuraBio. The registered enrollment target is 319 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02004522, a Phase 3 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 319 participants
- Enrollment target
Study Summary
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Primary Outcome
The primary efficacy endpoint for the study was PFS, defined as time from randomization to the first documentation of PD as determined by blinded independent review or death due to any cause.
Interventions
- DRUG Duvelisib
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2013-11 |
| Est. Completion | 2021-06 |
| Phase | Phase 3 |
What the finished NCT02004522 record still lists
NCT02004522 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Duvelisib is the first listed.
NCT02004522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02004522 about?
NCT02004522 is a clinical study titled "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)". A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
What is the current status of trial NCT02004522?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 319 participants. The study started on 2013-11. Estimated completion is 2021-06.
What interventions are being tested in trial NCT02004522?
The interventions under investigation include: Duvelisib (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT02004522?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02004522's enrollment target sits among peer trials
319 1087th of 2000 higher than 914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia